Published Date: 17 Mar 2023
A group of researchers from the annual meeting of the American Academy of Orthopedic Surgeons (AAOS) "analyzed the data and...
Read Full NewsScreening for insulin resistance early after the diagnosis of hidradenitis suppurativa shows promise for guiding therapies to improve the disease course.
At 52 weeks, the 30-mg daily oral dose of brepocitinib outperformed the 15-mg dose in a study of patients with dermatomyositis resistant to previous treatments.
Combination therapies remain key as multiple agents for melasma hit the market.
CHAMPION-AF finds left atrial appendage closure and anticoagulation therapy for atrial fibrillation about equal but raises doubts about whether the former is a true alternative.
For intermediate-risk pulmonary embolism, a low-dose fibrinolysis strategy reduced PE-related events by half with no significant increase in bleeding vs standard therapy.
A subgroup analysis of the VESALIUS-CV trial showed evolocumab significantly cut LDL cholesterol and cardiovascular event risk in people with diabetes but no known atherosclerosis.
Performed with favorable safety, the diagnostic yield for coronary function testing in patients with ischemia but nonobstructive arteries was found to exceed 90%.
1.
Early Results for Anorexia Nervosa with Psilocybin.
2.
Quads, Frailty, and the Future: Evolving Frontline Strategies in Multiple Myeloma
3.
Two medications might work better for breast cancers that are resistant to one.
4.
The most precise research tools for the deadliest blood cancer have been developed.
5.
Error on the MGUS-Autoimmune Disease Association.
1.
Immunotherapy Breakthroughs: Transforming Cancer Care Across All Oncology Fields
2.
Uncovering the Reality of Colon Cancer: A Look at Real Images
3.
Revolutionizing Lung Transplantation: The Promise of Donor-Specific Blood Transfusion
4.
Precision Oncology: Tailoring Cancer Treatment for the Individual
5.
AI Meets the Gut Microbiome: Early Detection of GI Malignancies Redefined
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation